Abstract
Objectives To present pertinent issues involved in radiation safety in radioimmunotherapy with 90Y ibritumomab tiuxetan. Data sources Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radiation safety and radioimmunotherapy. Conclusion Radioimmunotherapy with 90Y ibritumomab tiuxetan is safe and effective in the indicated opulation, and radiation safety requirements for caregivers and patients are minimal. Yttrium 90 ibritumomab is routinely and safely administered as an outpatient procedure; safety precautions are universal precautions, with the addition of acrylic shielding for the preparation and administration of the radiolabeled dose. Implications for nursing practice Oncology nurses play a key role in the multidisciplinary team. By observing universal precautions, and advising patients to do the same, oncology nurses may facilitate the safe and effective administration of the ibritumomab tiuxetan regimen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
